Wednesday, July 2, 2025 7/2/2025

Targeting Feedback Circuitry for Antiviral Therapy

Award Number: R01AI180651
ORGANIZATION: NATIONAL INSTITUTE OF ALLERGY & INFECTIOUS DISEASES
OPDIV: NIH
AWARD CLASS: DISCRETIONARY
AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)
PERIOD OF PERFORMANCE START DATE: 12/11/2023
PERIOD OF PERFORMANCE END DATE: 10/31/2028

Group Awards By:

View Award Description

Targeting Feedback Circuitry for Antiviral Therapy - PROJECT SUMMARY/ABSTRACT The human herpesvirus 5 (cytomegalovirus, CMV) infects >50% of the world’s population and causes substantial morbidity and mortality in immunocompromised persons. There is no approved vaccine and CMV is a leading cause of transplant failure and of birth defects. The current standard-of-care therapy for CMV (ganciclovir, GCV), suffers from rapid evolution of viral resistance arising from the extensive CMV genetic diversity in patients and there is an unmet clinical need for more effective CMV antivirals with high barriers to resistance. The long-term goal of this work is to develop antivirals that are resilient to the evolution of resistance. The specific objective of this proposal is to determine if targeting and disrupting viral transcriptional feedback circuits is a viable antiviral strategy with a high genetic barrier to the evolution of resistance. Over the past decade our studies characterized CMV’s master transcriptional circuit, a negative-feedback (i.e., auto-repressive) circuit called the immediate-early (IE) circuit. We discovered that this negative-feedback circuit functions to maintain homeostatic levels of the immediate-early 2 (IE86) protein, which is essential for CMV replication but also highly cytotoxic. Based on the conserved nature of this negative-feedback loop, we developed strategies to disrupt negative feedback and ‘open the loop’, generating cytotoxic levels of IE86 and dramatically inhibiting viral replication. Resistance to “open-loop lethality” is high and requires evolution of a genetically orthogonal feedback loop—a high genetic barrier—and led to our development of DNA duplexes that competitively inhibit feedback, now termed “feedback disruptor (FD) molecules”. Our extensive preliminary data show that FD molecules generate open-loop lethality in virus-infected cells, leading to multi-log (>100x) reduction in virus titers and protecting CMV-infected mice from death without detected toxicity. Based on these extensive preliminary data in animals, our central hypothesis is that disruption of IE feedback circuitry is a pharmacokinetically viable strategy with a high barrier to the evolution of resistance. The rationale for the FD approach rests upon our development of escape-resistant antivirals for other rapidly mutating viruses and an established body of literature demonstrating that recapitulating disrupted feedback loops carries a high genetic cost. The specific aims will test our hypothesis that feedback is pharmacokinetically druggable and resilient to the evolution of resistance by: (i) developing a new type of PK/PD, viral dynamics model of feedback disruptors to aid clinical translation of the antiviral strategy, (ii) testing if silencing of cell-death pathways is a mechanism for resistance to FD ‘open-loop lethality’ and (iii) determining the minimal viral genetic modifications that enable mutational escape from FDs, or if the resistance barrier can be overcome. These studies will have broad significance in establishing transcriptional feedback as a druggable target and quantifying the resistance barrier. Payoffs will be a first-in-class antiviral that could catalyze a new drug paradigm targeting feedback circuitry.


Issue Date FY	Funding FY	Legal Entity Name	Legal Entity Address	Legal Entity City	Legal Entity State	Legal Entity Zip Code	Legal Entity COUNTY	Legal Entity COUNTRY	Assistance Listing	Award Code	Budget Year	Action Date	Action Type	Action Amount

Issue Date FY: 2025 ( Subtotal = $1,510,374 )
2025	2025	AUTONOMOUS THERAPEUTICS INC	11808 AUTH LN	SILVER SPRING	MD	20902	MONTGOMERY	USA	Allergy and Infectious Diseases Research	003	2	3/25/2025	CHANGE OF GRANTEE / TRAINING INSTITUTION / AWARDING INSTITUTION	$794,033
2025	2025	AUTONOMOUS THERAPEUTICS INC	11808 AUTH LN	SILVER SPRING	MD	20902	MONTGOMERY	USA	Allergy and Infectious Diseases Research	001	2	12/4/2024	CHANGE OF GRANTEE / TRAINING INSTITUTION / AWARDING INSTITUTION	$1,510,374
2025	2024	J.DAVID GLADSTONE INSTITUTES	1650 OWENS ST	SAN FRANCISCO	CA	94158	SAN FRANCISCO	USA	Allergy and Infectious Diseases Research	000	1	12/4/2024	NEW	$0
2025	2024	J.DAVID GLADSTONE INSTITUTES	1650 OWENS ST	SAN FRANCISCO	CA	94158	SAN FRANCISCO	USA	Allergy and Infectious Diseases Research	002	1	3/25/2025	NEW	-$794,033
														Subtotal = $1,510,374

Issue Date FY: 2024 ( Subtotal = $944,989 )
2024	2024	J.DAVID GLADSTONE INSTITUTES	1650 OWENS ST	SAN FRANCISCO	CA	94158	SAN FRANCISCO	USA	Allergy and Infectious Diseases Research	000	1	12/11/2023	NEW	$850,489
2024	2024	J.DAVID GLADSTONE INSTITUTES	1650 OWENS ST	SAN FRANCISCO	CA	94158	SAN FRANCISCO	USA	Allergy and Infectious Diseases Research	001	1	6/3/2024	NEW	$94,500
														Subtotal = $944,989

Grand Total All Awards = $2,455,363

Top

All Categories

About

Search

Reports

Data Submission

Award Information

Targeting Feedback Circuitry for Antiviral Therapy

Award Number: R01AI180651

ORGANIZATION: NATIONAL INSTITUTE OF ALLERGY & INFECTIOUS DISEASES

OPDIV: NIH

AWARD CLASS: DISCRETIONARY

AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)

PERIOD OF PERFORMANCE START DATE: 12/11/2023

PERIOD OF PERFORMANCE END DATE: 10/31/2028

Federal Websites

Department of Health & Human Services

HHS Operating Divisions

HHS Staff Divisions

Download A Document Viewer